Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.
Rotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with that in animals immunized by the i.n. route. Humoral and cellular immune responses induced by these immunization protocols were analyzed. We found that although i.r. immunization with 2/6-VLPs induces lower RV-specific immunoglobulin G (IgG) and IgA levels in serum, intestinal anti-RV IgA production is higher in mice immunized by the i.r. route. Cellular immune response has been evaluated by measuring cytokine production by spleen and Peyer's patch cells (PPs) after ex vivo restimulation with RV. Mice immunized by the i.n. and i.r. routes display higher gamma interferon production in spleen and PPs, respectively. In conclusion, we demonstrate that i.r. immunization with 2/6-VLPs protects against RV infection in mice and is more efficient than i.n. immunization in inducing an anti-RV immune response in intestinal mucosa.
Agnello
Davide
D
Laboratoire de Virologie et Centre National de Référence des Virus Entériques, CHU et Faculté de Médecine, Université de Bourgogne, 7 boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Davide.Agnello@u-bourgogne.fr
Hervé
Christine A
CA
Lavaux
Amandine
A
Darniot
Magali
M
Guillon
Patrice
P
Charpilienne
Annie
A
Pothier
Pierre
P
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002772:Cholera Toxin / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D007114:Immunization; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis; D007413:Intestinal Mucosa / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D012007:Rectum / Q000276:immunology; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014771:Virion / Q000276:immunology*
D000914:Antibodies, Viral; C408982:CPG-oligonucleotide; D016207:Cytokines; D007071:Immunoglobulin A, Secretory; D009838:Oligodeoxyribonucleotides; D022243:Rotavirus Vaccines; D002772:Cholera Toxin